百利天恒：iza-bren聯合用藥獲2個II/III期臨床試驗批准

每日經濟新聞

5小時前

每經AI快訊，4月1日，百利天恒(688506.SH)公告稱，公司近日收到國家藥監局簽發的2個《藥物臨床試驗批准通知書》，公司自主研發的創新生物藥iza-bren(EGFR×HER3雙抗ADC)的2個聯合用藥方案獲得批准。獲批適應症包括：聯合阿比特龍±奧拉帕利、聯合奧拉帕利用於去勢抵抗性前列腺癌；聯合貝伐珠單抗±化療、聯合奧拉帕利±貝伐珠單抗±化療用於晚期卵巢癌。目前，該藥物已有7項適應症被納入...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2624123594"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2624123594\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2624123594?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-04-01 18:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624123594","market":"sh","top_or_hot":-1,"title":"百利天恒：iza-bren聯合用藥獲2個II/III期臨床試驗批准","media":"每日經濟新聞","content":"<div>\n<p>每經AI快訊，4月1日，百利天恒(688506.SH)公告稱，公司近日收到國家藥監局簽發的2個《藥物臨床試驗批准通知書》，公司自主研發的創新生物藥iza-bren(EGFR×HER3雙抗ADC)的2個聯合用藥方案獲得批准。獲批適應症包括：聯合阿比特龍±奧拉帕利、聯合奧拉帕利用於去勢抵抗性前列腺癌；聯合貝伐珠單抗±化療、聯合奧拉帕利±貝伐珠單抗±化療用於晚期卵巢癌。目前，該藥物已有7項適應症被納入...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202604013692048171.html\">網頁鏈接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百利天恒：iza-bren聯合用藥獲2個II/III期臨床試驗批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百利天恒：iza-bren聯合用藥獲2個II/III期臨床試驗批准\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">每日經濟新聞</strong><span class=\"h-time small\">2026-04-01 18:06</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>每經AI快訊，4月1日，百利天恒(688506.SH)公告稱，公司近日收到國家藥監局簽發的2個《藥物臨床試驗批准通知書》，公司自主研發的創新生物藥iza-bren(EGFR×HER3雙抗ADC)的2個聯合用藥方案獲得批准。獲批適應症包括：聯合阿比特龍±奧拉帕利、聯合奧拉帕利用於去勢抵抗性前列腺癌；聯合貝伐珠單抗±化療、聯合奧拉帕利±貝伐珠單抗±化療用於晚期卵巢癌。目前，該藥物已有7項適應症被納入...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202604013692048171.html\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://finance.eastmoney.com/a/202604013692048171.html\">每日經濟新聞</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4134","symbol_name":"信息科技諮詢與其它服務","start_time":0,"source_url":"http://finance.eastmoney.com/a/202604013692048171.html","article_id":"2624123594","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604013692048171.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624123594","pubTimestamp":1775038011,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"每經AI快訊，4月1日，百利天恒(688506.SH)公告稱，公司近日收到國家藥監局簽發的2個《藥物臨床試驗批准通知書》，公司自主研發的創新生物藥iza-bren(EGFR×HER3雙抗ADC)的2個聯合用藥方案獲得批准。獲批適應症包括：聯合阿比特龍±奧拉帕利、聯合奧拉帕利用於去勢抵抗性前列腺癌；聯合貝伐珠單抗±化療、聯合奧拉帕利±貝伐珠單抗±化療用於晚期卵巢癌。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"91194":"临工重机股份有限公司（临时代码）","688506":"百利天恒","BK4134":"信息科技咨询与其它服务","BK0239":"医药制造","02615":"百利天恒","III":"信息服务"},"translate_title":"Baili Tianheng: iza-bren combination was approved for 2 phase II/III clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91194":1.5,"688506":1.5,"III":1.5,"02615":1.5},"content_text":"每經AI快訊，4月1日，百利天恒(688506.SH)公告稱，公司近日收到國家藥監局簽發的2個《藥物臨床試驗批准通知書》，公司自主研發的創新生物藥iza-bren(EGFR×HER3雙抗ADC)的2個聯合用藥方案獲得批准。獲批適應症包括：聯合阿比特龍±奧拉帕利、聯合奧拉帕利用於去勢抵抗性前列腺癌；聯合貝伐珠單抗±化療、聯合奧拉帕利±貝伐珠單抗±化療用於晚期卵巢癌。目前，該藥物已有7項適應症被納入突破性治療品種名單，其中鼻咽癌和食管鱗癌兩個適應症的上市申請已獲受理並進入優先審評程序。（文章來源：每日經濟新聞）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}